Biotechnology Assets [BST] vs Oryzon Genomics S.A [ORY] Detailed Stock Comparison
Biotechnology Assets
BME
Loading...
Oryzon Genomics S.A
BME
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Biotechnology Assets wins in 4 metrics, Oryzon Genomics S.A wins in 12 metrics, with 0 ties. Oryzon Genomics S.A appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Biotechnology Assets | Oryzon Genomics S.A | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 10.77 | -47.70 | Oryzon Genomics S.A |
| Price-to-Book Ratio | 3.85 | 1.87 | Oryzon Genomics S.A |
| Debt-to-Equity Ratio | 31.56 | 15.87 | Oryzon Genomics S.A |
| PEG Ratio | N/A | -16.24 | N/A |
| EV/EBITDA | -21.06 | -40.09 | Oryzon Genomics S.A |
| Profit Margin (TTM) | -98.39% | -56.48% | Oryzon Genomics S.A |
| Operating Margin (TTM) | -38.88% | 6.30% | Oryzon Genomics S.A |
| EBITDA Margin (TTM) | N/A | 6.30% | N/A |
| Return on Equity | -44.40% | -4.20% | Oryzon Genomics S.A |
| Return on Assets (TTM) | -9.11% | -2.52% | Oryzon Genomics S.A |
| Free Cash Flow (TTM) | $-794,574 | $-13.40M | Biotechnology Assets |
| 1-Year Return | 18.75% | 94.59% | Oryzon Genomics S.A |
| Price-to-Sales Ratio (TTM) | 8.90 | 28.64 | Biotechnology Assets |
| Enterprise Value | $27.22M | $197.07M | Oryzon Genomics S.A |
| EV/Revenue Ratio | 9.18 | 26.38 | Biotechnology Assets |
| Revenue per Share (TTM) | $0 | $0 | Oryzon Genomics S.A |
| Earnings per Share (Diluted) | $-0.04 | $-0.06 | Biotechnology Assets |
| Beta (Stock Volatility) | 1.77 | 0.43 | Oryzon Genomics S.A |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Biotechnology Assets vs Oryzon Genomics S.A Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Biotechnology Assets | -1.32% | -2.56% | -2.56% | 15.15% | 15.15% | 35.71% |
| Oryzon Genomics S.A | -8.61% | 31.39% | 30.43% | 36.36% | 18.03% | 140.00% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Biotechnology Assets | 18.75% | 280.00% | -15.56% | -88.13% | -83.19% | -83.19% |
| Oryzon Genomics S.A | 94.59% | 71.43% | 24.14% | 1.41% | 1.41% | 1.41% |
News Based Sentiment: Biotechnology Assets vs Oryzon Genomics S.A
Biotechnology Assets
News sentiment data is not available for Biotechnology Assets at this time.
Oryzon Genomics S.A
News based Sentiment: POSITIVE
September was a pivotal month for Oryzon Genomics, characterized by a strategic expansion into the sickle cell disease market, a successful capital raise, and strengthening of its intellectual property portfolio. These developments significantly enhance the company's growth prospects and investor confidence, making it a noteworthy month for the company.
Performance & Financial Health Analysis: Biotechnology Assets vs Oryzon Genomics S.A
| Metric | BST | ORY |
|---|---|---|
| Market Information | ||
| Market Cap | €25.64M | €217.81M |
| Market Cap Category | Small cap | Mid cap |
| 10 Day Avg. Volume | 351,982 | 223,440 |
| 90 Day Avg. Volume | 357,404 | 323,774 |
| Last Close | €0.37 | €3.29 |
| 52 Week Range | €0.24 - €0.49 | €1.40 - €3.69 |
| % from 52W High | -23.52% | -10.84% |
| All-Time High | €13.98 (Jun 23, 2014) | €5.25 (Dec 14, 2015) |
| % from All-Time High | -97.35% | -37.33% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.18% | 0.03% |
| Quarterly Earnings Growth | N/A | N/A |
| Financial Health | ||
| Profit Margin (TTM) | -0.98% | -0.56% |
| Operating Margin (TTM) | -0.39% | 0.06% |
| Return on Equity (TTM) | -0.44% | -0.04% |
| Debt to Equity (MRQ) | 31.56 | 15.87 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | €0.10 | €1.47 |
| Cash per Share (MRQ) | €0.00 | €0.40 |
| Operating Cash Flow (TTM) | €-73,854 | €-3,027,877 |
| Levered Free Cash Flow (TTM) | €347,742 | €-10,217,728 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Biotechnology Assets vs Oryzon Genomics S.A
| Metric | BST | ORY |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 10.77 | -47.70 |
| Forward P/E | N/A | -16.24 |
| PEG Ratio | N/A | -16.24 |
| Price to Sales (TTM) | 8.90 | 28.64 |
| Price to Book (MRQ) | 3.85 | 1.87 |
| Market Capitalization | ||
| Market Capitalization | €25.64M | €217.81M |
| Enterprise Value | €27.22M | €197.07M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 9.18 | 26.38 |
| Enterprise to EBITDA | -21.06 | -40.09 |
| Risk & Other Metrics | ||
| Beta | 1.77 | 0.43 |
| Book Value per Share (MRQ) | €0.10 | €1.47 |
Financial Statements Comparison: Biotechnology Assets vs Oryzon Genomics S.A
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BST | ORY |
|---|---|---|
| Revenue/Sales | N/A | €0 |
| Cost of Goods Sold | N/A | N/A |
| Gross Profit | N/A | N/A |
| Research & Development | N/A | €784,261 |
| Operating Income (EBIT) | N/A | €537,748 |
| EBITDA | N/A | €928,484 |
| Pre-Tax Income | N/A | €-1.41M |
| Income Tax | N/A | €-1.51M |
| Net Income (Profit) | N/A | €101,707 |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BST | ORY |
|---|---|---|
| Cash & Equivalents | €143,822 | €31.11M |
| Total Current Assets | €3.70M | €34.14M |
| Total Current Liabilities | €4.55M | €13.01M |
| Long-Term Debt | €2.39M | €5.05M |
| Total Shareholders Equity | €6.61M | €114.22M |
| Retained Earnings | €-23.57M | €-20.93M |
| Property, Plant & Equipment | €481,199 | €1.08M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BST | ORY |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BST | ORY |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 351,982 | 223,440 |
| Average Daily Volume (90 Day) | 357,404 | 323,774 |
| Shares Outstanding | 65.97M | 64.75M |
| Float Shares | N/A | 61.35M |
| % Held by Insiders | 0.49% | 0.21% |
| % Held by Institutions | 0.00% | 0.04% |
Dividend Analysis & Yield Comparison: Biotechnology Assets vs Oryzon Genomics S.A
| Metric | BST | ORY |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |